Click here for slides on this topic


Incretin

A hormone released by the gut in response to food that helps to regulate glucose levels in the body. GLP-1 is an example of an incretin hormone.


The following content matched the glossary term: Incretin

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

Clinical Insights April 2013

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

Once-weekly exenatide vs once- or twice-daily insulin detemir: efficacy and safety in patients with type 2 diabetes

Top

Davies M, Heller S, Sreenan S, et al. Once weekly exenatide versus once or twice daily insulin detemir randomized, open label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013;36(5):1368-1376. Type 2 diabetes is often linked to obesity and requires multiple interventions to achieve A1C goals. Thus, treatments that improve glycemia and body weight with low hypoglycemia risk may be more beneficial than treatments that cause weight gain.

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

Clinical Insights in Diabetes Newsletter December 2012

Top

Clinical Insights® in Diabetes newsletter December 2012 

Once-weekly exenatide vs once-daily liraglutide in DURATION-6, HDL-C and microvascular risk in ADVANCE, statins and valvular calcification in VADT, bariatric surgery and cardiovascular events in obesity and type 2 diabetes in SOS. 

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Top

Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention with Exenatide Once-Weekly) is a series of multinational studies comparing once-weekly exenatide with other antihyperglycemic therapies for treatment of type 2 diabetes.

Clinical Insights in Diabetes Newsletter November 2012

Top

Clinical Insights® in Diabetes Newsletter November 2012.

Statins and diabetes, Roux-en-Y for type 2 diabetes and obesity, sitagliptin or liraglutide for type 2 diabetes treatment, obesity and mortality, and DPP-4 inhibitors and cardiovascular disease.

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

Efficacy & safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 wks in metformin-treated patients

Top

Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993. In 2011, Pratley and colleagues reported 52-week data from a trial that explored treatment with the DPP-4 inhibitor, sitagliptin, and the GLP-1 receptor agonist, liraglutide, among subjects with type 2 diabetes and A1C 7.5%–10%.

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: Incretin Slides Found: 34
Exenatide: Clinical Pharmacology
Exenatide: Effects on Glycemic Control in Combination With Current Oral Therapies
Exenatide: Proportion of Patients Achieving A1C <=7%
Glucagon-Like Peptide-1
GLP-1 Release Is Reduced in Type 2 Diabetes
Exenatide: Effect on the Beta-Cell
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Change in Body Weight Following 82 Weeks of Exenatide Treatment
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
Effects of Exenatide LAR on A1C in Patients With Type 2 Diabetes
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
12-Week Saxagliptin Improves Glycemic Control in Drug-Naïve Patients
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI